Biolife Solutions CMO Todd Berard sells shares worth $7,514 By


In a recent transaction, Todd Berard, the Chief Marketing Officer of Biolife Solutions Inc (NASDAQ:BLFS), sold 345 shares of company stock. The sale, which took place on May 29, 2024, was executed at a price of $21.78 per share, resulting in a total transaction value of $7,514.

The transaction was carried out in accordance with a Rule 10b5-1(c) trading plan, which Berard had adopted on February 24, 2022, to satisfy tax withholding obligations related to the vesting of restricted stock. Following this sale, Berard’s remaining holdings in Biolife Solutions amount to 118,894 shares of common stock.

Investors often monitor insider transactions as they can provide insights into the executive’s view of the company’s current valuation and future prospects. However, it is important to consider that trades under a 10b5-1 plan are pre-scheduled to occur at a predetermined time, which means they do not necessarily reflect any change in the executive’s sentiment towards the company.

Biolife Solutions, a company specializing in electromedical and electrotherapeutic apparatus, is incorporated in Delaware and has its business address in Bothell, Washington. The company’s shares are traded on the NASDAQ under the ticker symbol BLFS.

InvestingPro Insights

In light of the recent insider transaction at Biolife Solutions Inc (NASDAQ:BLFS), where Chief Marketing Officer Todd Berard sold shares, investors may be seeking additional context to understand the company’s financial health and market performance. Here are some curated insights from InvestingPro that could provide further clarity:

InvestingPro Data indicates that Biolife Solutions has a market capitalization of $988.74 million, reflecting the company’s size and market value as of Q1 2024. Despite the company’s significant market presence, it has been experiencing a downward trend in revenue, with a decline of -15.89% over the last twelve months as of Q1 2024. Moreover, the company’s P/E ratio stands at -17.27, suggesting that investors are currently valuing the company at a loss, expecting future growth or profitability to potentially justify the current share price.

From the perspective of InvestingPro Tips, it’s notable that analysts have revised their earnings upwards for the upcoming period, which may indicate a potential turnaround or positive developments that are not yet reflected in the company’s financial statements. Additionally, investors should be aware that analysts do not anticipate the company to be profitable this year, aligning with the negative P/E ratio.

For those looking for a deeper dive into Biolife Solutions’ financial and market performance, there are additional InvestingPro Tips available on the platform. For example, the company’s stock price movements have been quite volatile, which could be of interest to investors with a higher risk tolerance. Biolife Solutions does not pay a dividend to shareholders, which may influence the investment decisions of those seeking regular income streams from their investments.

Investors interested in these metrics and more can access additional insights on Biolife Solutions by visiting Furthermore, by using the coupon code PRONEWS24, new subscribers can get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. Currently, there are over 10 additional InvestingPro Tips available for Biolife Solutions, providing a comprehensive analysis for informed investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Source link

Leave A Reply

Your email address will not be published.